Characteristics of 20 HIV-1 infected patients included in the study.

*Patients were selected due to a failing ART with the exception of patients no 2, 13, 16, 19 who were infected with an NNRTI-resistant strain and a treatment naïve patient no 4 who had the K103R mutation; a and b indicate a first and a second sample; m: male; f: female; age: years;**Figure within brackets indicate the number of weeks from the start of the last ongoing NNRTI-treatment to the sampling date.***Figure within brackets indicates the number of weeks from cessation of the prior NNRTI-containing treatment to the sampling date.****ABC: abacavir; 3TC: lamivudine; FTC: emitricitabine; TDF: tenofovir; ZDV: zidovudine: LPV/r: lopinavir/ritonavir; ATV/r: atazanavir/ritonavir: DRV/r: darunavir/ritonavir; RAL: raltegravir; T20: enfuvirtid.